Low serum interleukin-6 levels as a predictive marker of recurrence in patients with hepatitis B virus related hepatocellular carcinoma who underwent curative treatment |
| |
| Institution: | 1. Department of Gastroenterology, Ajou University School of Medicine, Suwon, Republic of Korea;2. Department of Radiology, Ajou University School of Medicine, Suwon, Republic of Korea;3. Department of Surgery, Ajou University School of Medicine, Suwon, Republic of Korea;2. Beth Israel Medical Center, New York, NY, USA;3. Department of Public Health, Faculty of Medicine, University of Tartu, Tartu, Estonia;1. PCR Hepatitis Lab, Dept. of Medicine, Maulana Azad Medical College, University of Delhi, New Delhi 110002, India;2. Department of Medical Microbiology, Maulana Azad Medical College, University of Delhi, New Delhi 110002, India;1. Department of Gastroenterology and Nephrology, Chiba University, Graduate School of Medicine, Chiba 260-8670, Japan;2. Department of Molecular Virology, Chiba University, Graduate School of Medicine, Chiba 260-8670, Japan;1. Central Laboratory, Lanzhou University Second Hospital, Lanzhou, Gansu 730030, PR China;2. Gansu Provincial Key Laboratory of Digestive System Tumors, Lanzhou University Second Hospital, Lanzhou, Gansu 730030, PR China;3. Clinical Laboratory, Lanzhou University Second Hospital, Lanzhou, Gansu 730030, PR China;1. Molecular Biology Department, Genetic Engineering and Biotechnology Research Institute (GEBRI), University of Sadat City, Egypt;2. Hepatology Department, National Liver Institute (NLI), Menoufiya University, Shebeen El-Kom, Menoufiya, Egypt;3. Biochemistry Department, National Liver Institute (NLI), Menoufiya University, Shebeen El-Kom, Menoufiya, Egypt |
| |
| Abstract: | BackgroundWe aimed to investigate the use of novel serum biomarkers for predicting the recurrence and survival of patients with hepatitis B virus (HBV)-related early hepatocellular carcinoma (HCC) after hepatic resection or radiofrequency ablation (RFA).MethodsOne hundred and five patients with HBV-related HCC, who fulfilled the Milan criteria without vascular invasion and underwent hepatic resection or RFA, were followed-up for a median duration of 52 months. Pretreatment serum concentrations of 16 cytokines including interleukin-6 (IL-6) were measured by using a Luminex 200 system. The measured serum cytokines and several clinical factors were analyzed retrospectively.ResultsUnivariate analysis showed that patients with lower pretreatment serum levels of IL-10, IL-6, monocyte chemoattractant protein-1, and tumor necrosis factor-α had significantly shorter disease-free survival (DFS) than those with higher levels. Multivariate analysis revealed that a low serum IL-6 level (?33.00 pg/mL; hazard ratio HR] = 5.39; 95% confidence interval CI] = 1.27–22.93; P = 0.022), low platelet count (<100 × 109/L; HR = 2.23; 95% CI = 1.28–3.89; P = 0.005), and low serum albumin level (?3.5 g/L; HR = 2.26; 95% CI = 1.28–3.97; P = 0.005) had a negative prognostic impact on DFS. In the analysis for overall survival, a low serum platelet level (<100 × 109/L; HR = 2.80; 95% CI = 1.31–5.99; P = 0.008) and multiple tumor (?2; HR = 4.05; 95% CI = 1.56–10.48; P = 0.004) showed a negative prognostic impact on the overall survival.ConclusionA low serum IL-6 level is, in addition to low platelet count and low serum albumin level, an independent prognostic factor for DFS in patients with HBV-related early HCC who underwent hepatic resection or RFA with curative intention. |
| |
| Keywords: | Cytokine Hepatitis B chronic Prognosis Hepatocellular carcinoma |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
